[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"follicular-lymphoma--fl\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:follicular-lymphoma--fl":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,9,0,[8,53,87,119,147,186,211,239,265],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":32,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":42,"lastUpdatePostDateStruct":43,"startDateStruct":46,"completionDateStruct":48,"leadSponsor":50,"locationsCount":4},"100641819","connected-blood-pressure-monitoring-in-patients-with-hematologic-malignancies-initiating-covalent-btk-inhibitors-100641819",false,"NCT07592481","Connected Blood Pressure Monitoring in Patients With Hematologic Malignancies Initiating Covalent BTK Inhibitors","HEMO-CONNECT","Inclusion Criteria:\n\n* Age ≥18 years\n* Diagnosis of lymphoid malignancy: chronic lymphocytic leukemia, follicular lymphoma, marginal zone lymphoma, lymphoplasmacytic lymphoma, Waldenström macroglobulinemia, or mantle cell lymphoma\n* Initiation of oral BTK inhibitor therapy (ibrutinib, acalabrutinib, or zanubrutinib), in treatment-naive or relapsed patients\n* Affiliation with a social security system\n* Signed written informed consent\n\nExclusion Criteria:\n\n* Known cognitive impairment\n* No internet access\n* Individuals under guardianship, curatorship, or legal protection","ALL","18 Years",{"count":19,"type":20},40,"ESTIMATED","INTERVENTIONAL",[23],"NA","This pilot prospective study aims to evaluate adherence to home blood pressure monitoring using connected blood pressure (BP) devices in patients with malignant B-cell hemopathies initiating covalent Bruton tyrosine kinase inhibitors (cBTKi). The objective is to determine whether digital BP monitoring improves early detection and management of BTKi-induced hypertension over 6 months.",[26,27,28,29,30,31],"Chronic Lymphocytic Leukemia (CLL)","Follicular Lymphoma ( FL)","Waldenstrom Macroglobulinaemia","Lymphoplasmacytic Lymphoma","Marginal Zone B Cell Lymphoma","Mantle Cell Lymphoma",[33,34,35,36,37,38,39,40],"BTK inhibitor","Hypertension","Telemonitoring","Connected device","Blood pressure","Lymphoid malignancies","Advanced practice nursing","Cardio-oncology","NOT_YET_RECRUITING","2026-06-18",{"date":44,"type":45},"2026-06-22","ACTUAL",{"date":47,"type":20},"2026-07-01",{"date":49,"type":20},"2027-12-31",{"name":51,"class":52},"Centre Hospitalier de la côte Basque","OTHER",{"id":54,"slug":55,"hasResults":11,"nctId":56,"briefTitle":57,"officialTitle":57,"acronym":58,"eligibilityCriteria":59,"healthyVolunteers":11,"sex":16,"minAge":60,"maxAge":4,"enrollmentInfo":61,"targetDuration":63,"studyType":64,"phases":4,"briefSummary":65,"conditions":66,"keywords":68,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":86},"100604846","a-longitudinal-multi-center-molecular-biomarker-discovery-registry-for-patients-with-hematologic-malignancies-100604846","NCT07154823","A Longitudinal Multi-Center Molecular Biomarker Discovery Registry for Patients With Hematologic Malignancies","Aquarius","All Cohorts Inclusion Criteria:\n\n1. Willing and able to participate in the research and provide biospecimens\n2. Willing and able to provide informed consent\n\nCohort 001 Inclusion:\n\n1. Have documented diagnosis of AML according to the World Health Organization (WHO) classification\n2. Secondary AML is allowed\n\nCohort 002 Inclusion:\n\n1. Histologically confirmed diagnosis of Follicular Lymphoma (Subgroups A-D)\n2. Submission of baseline sample representative of current disease per laboratory manual (Subgroups A-D)\n3. 002A (Newly Diagnosed Active Observation): On active observation for 6 more or less, or intended for active observation\n4. 002B (Newly Diagnosed, High Risk): Intended for first line treatment\n5. 002B (Newly Diagnosed, High Risk): Meets the criteria for high risk by any of the following: Follicular Lymphoma Inernational Prognostic Index (FLIPI) High Risk, Groupe d'Etude des Lymphomes Follicularies (GELF) High Tumor Burden, Lactate Dehydrogenase (LDH) above the upper limit of normal (ULN)\n6. 002C (Relapsed \u002F Refractory High Risk POD24 FL): Documented progression of disease within 24 months (POD24) of first line follicular lymphoma treatment, prior to second line treatment\n7. 002D (Transformed FL): Pathologically confirmed transformation\n\nAll Cohorts Exclusion Criteria:\n\n1\\. Not willing or able to adhere with the study procedures\n\nCohort 001:\n\n1\\. Have received any prior therapy intended for standard of care (SoC) treatment of AML\n\nCohort 002:\n\n1. 002A: Received prior treatment for follicular lymphoma\n2. 002A: Diagnosed with High Risk follicular lymphoma by any of the following definitions: FLIPI High Risk, GELF High Tumor Burden, LDH above ULN\n3. 002A: Resected patients with NED\n4. 002B: Intended for active observation\n5. 002B: Received prior treatment for follicular lymphoma","0 Years",{"count":62,"type":20},550,"5 Years","OBSERVATIONAL","The TEMPUS AQUARIUS Study is a non-interventional, longitudinal observational study focused on hematological malignancies. It will collect rich molecular (multi-omic) and clinical data from patient cohorts through serial blood draws and the acquisition of leftover tissue and\u002For bone marrow aspirates during their routine therapy and disease monitoring. The primary goal is to understand the association between biomarkers and real-world clinical outcomes in these patient populations.",[67,27],"Acute Myeloid Leukaemia (AML)",[69,70,71,72,73,74],"Hematologic Malignancy","Acute Myeloid Leukemia","AML","Next Generation Sequencing","NGS","Follicular Lymphoma","RECRUITING","2026-06-11",{"date":78,"type":45},"2026-06-15",{"date":80,"type":45},"2026-01-27",{"date":82,"type":20},"2035-11",{"name":84,"class":85},"Tempus AI","INDUSTRY",6,{"id":88,"slug":89,"hasResults":11,"nctId":90,"briefTitle":91,"officialTitle":92,"acronym":93,"eligibilityCriteria":94,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":95,"enrollmentInfo":96,"targetDuration":4,"studyType":21,"phases":98,"briefSummary":100,"conditions":101,"keywords":107,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":109,"lastUpdatePostDateStruct":110,"startDateStruct":112,"completionDateStruct":114,"leadSponsor":116,"locationsCount":118},"100570180","phase-1-a-study-to-evaluate-the-safety-and-clinical-activity-of-gf--cart01-cd2019-car-t-cell-in-subjects-with-relapsed-or-refractory-b-cell-hematological-malignancies-100570180","NCT06703892","A Study to Evaluate the Safety and Clinical Activity of GF- CART01 (CD20\u002F19 CAR T Cell) in Subjects With Relapsed or Refractory B-Cell Hematological Malignancies","An Open-Label, Non-Randomized, Phase I, Prospective, Dose- Finding Study to Evaluate the Safety and Clinical Activity of GF- CART01 (CD20\u002F19 CAR T Cell) in Subjects With Relapsed or Refractory B-Cell Hematological Malignancies","CD20\u002F19 CAR T","Inclusion Criteria:\n\n1. Subjects must be of age ≥ 18 years and ≤ 70 years\n2. Subjects or their legal guardians must volunteer to participate in the study and sign the informed consent\n3. Histologically confirmed diagnosis of Diffuse Large B-Cell Lymphoma - Not Otherwise Specified (DLBCL-NOS), follicular lymphoma (FL), Primary Mediastinal Large B-cell Lymphoma (PMBCL), or High-Grade B-Cell Lymphoma (HGBCL) per the world health organization (WHO) Classification Criteria for Lymphoma (2022)\n4. Tumor cell surface expression of CD19 (+) and\u002For CD20 (+) by flow cytometry or immunohistochemistry staining\n5. Relapsed, progressive or refractory disease (defined as have not achieved a complete response) after ≥ two lines of systemic therapy, including anti-CD20 antibody and anthracycline and\u002For Relapsed, progressive or refractory disease ( defined as have not achieved a complete response) after auto-HSCT\n6. Subjects have any accessible PET-positive lesion or measurable CT-positive lesion per Lugano 2014 criteria\n7. Adequate hematologic function: absolute neutrophil count (ANC) \\> 1,000\u002FμL, absolute lymphocyte count (ALC) \\> 300\u002FμL, platelet count ≥ 75,000\u002FμL, hemoglobin ≥ 8.0 g\u002FdL\n8. Adequate hepatic function: alanine aminotransferase (ALT) ≤ 5 times upper limit of normal (ULN), aspartate transaminase (AST) ≤ 5 times ULN, total bilirubin ≤ 1.5 times ULN\n9. Adequate renal function: blood estimated glomerular filtration rate (eGFR) ≥ 60 mL\u002Fmin\u002F1.73m2 (calculated by Modification of Diet in Renal Disease (MDRD) equation)\n10. Adequate cardiac function: echocardiogram or multigated blood pool analysis (MUGA) shows left ventricular ejection fraction (LVEF) ≥ 50%; and no clinically significant electrocardiogram (ECG) findings\n11. Adequate pulmonary function: no active infection in the lungs, blood oxygen saturation in indoor air ≥ 92%\n12. No clinically significant pleural effusion determined by the investigators\n13. Estimated survival time ≥ 3 months\n14. Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2\n15. Willingness and ability to comply with protocol-stated requirements, instructions, and restrictions in the investigator's judgement\n\nExclusion Criteria:\n\n1. Previously treated with any CAR T cell product or allogenic hematopoietic stem cell transplant (HSCT)\n2. Known or suspected allergy, hypersensitivity, or intolerance to any ingredients of the investigational product (IP)\n3. Known medical history or possible risk for taking contrast agent(s) for positron emission tomography (PET) and\u002For computed tomography (CT) scan\n4. Received any other investigational product, cell therapy, or gene therapy within 12 weeks prior to the leukapheresis\n5. Received any tyrosine kinase inhibitor within 2 weeks prior to the leukapheresis\n6. Received any systemic steroid, immunotherapy (such as immune checkpoint inhibitors, T- cell transfer therapies, monoclonal antibodies), or chemotherapy within 4 weeks prior to the leukapheresis\n7. Received any live vaccine from 2 weeks prior to the leukapheresis\n8. Subjects with human immunodeficiency virus (HIV), syphilis, Hepatitis B or C infection: HIV-1 and HIV-2 antibody positive, syphilis antibody positive, both hepatitis B virus (HBV) DNA and hepatitis B core (HBc) antibody positive, or hepatitis C virus (HCV) antibody positive\n9. Subjects with atrial or ventricular involvement by B-cell malignancies\n10. Subjects with tumor mass requiring urgent treatment within 8 weeks prior to the leukapheresis, such as ileus, tumor lysis syndrome, or vascular compression\n11. Subjects with severe disease or other uncontrolled diseases, such as coronary heart disease, angina pectoris, myocardial infarction, arrhythmia (urgent intervention indicated, life- threatening consequences, or hemodynamic compromise), cardiac angioplasty or stenting, unstable angina, cerebral thrombosis, cerebral hemorrhage, hypertension (systolic blood pressure ≥ 140 mmHg and\u002For diastolic blood pressure ≥ 90 mmHg)\n12. Unstable pulmonary embolism, deep venous embolism, or other major arterial\u002Fvenous thromboembolism events that occurred within 6 weeks prior to the leukapheresis. If subjects receive anticoagulant therapy, the treatment dose and frequency must be stable for more than 14 weeks prior to the leukapheresis\n13. History of craniocerebral trauma, disturbance of consciousness, epilepsy, cerebrovascular ischemia, cerebrovascular hemorrhagic diseases, dementia, cerebellar disease, or any autoimmune disease with central nervous system (CNS) involvement\n14. Female subject of childbearing potential who: a. Has positive pregnancy test result; or b. Is lactating\n15. Female subjects of childbearing potential, or male subject with female spouse\u002Fpartner of childbearing potential, who refuses to adopt at least one form of birth control from the date of signing informed consent to 12 months after GF-CART01 infusion. Acceptable forms of birth control include: a. Established use of oral, injected or implanted hormonal methods of contraception b. Placement of an intrauterine device (IUD) or intrauterine system (IUS) c. Barrier methods of contraception: condom or occlusive cap (diaphragm or cervical\u002Fvault caps)\n16. Any following situations that the investigators believe are not suitable for this trial and\u002For may increase the risk for subjects or interfere with the results of the study a. With severe active infections (except simple urinary tract infection and bacterial pharyngitis) b. With active central nervous system involvement by lymphoma, malignant cells in cerebrospinal fluid c. History of brain metastasis d. With uncontrolled malignancies e. Any toxicities due to prior therapy f. With any uncontrolled illness or a history of any illness","70 Years",{"count":97,"type":20},18,[99],"PHASE1","This is a Phase I, prospective, dose-finding study to evaluate the safety, persistence, and clinical activity of GF-CART01 in subjects aged 18-70 with relapsed or refractory (R\u002FR) B-cell hematological malignancies and failure of two-line or more standard chemotherapies or auto-hematopoietic stem cell transplantation (HSCT).This study is a traditional 3+3 dose-escalation design to observe dose-limiting toxicity (DLT), establish the maximum tolerated dose(MTD)\u002Frecommended phase 2 doses (RP2D), and preliminary efficacy of GF-CART01. RP2D may equal to or lower than MTD",[102,103,27,104,105,106],"Diffuse Large B Cell Lymphoma Relapsed","Diffuse Large B Cell Lymphoma Refractory","Primary Mediastinal Large B-Cell Lymphoma-Refractory","Primary Mediastinal Large B-Cell Lymphoma-Recurrent","High-grade B-cell Lymphoma (HGBCL)",[108],"CAR T","2026-06-10",{"date":111,"type":45},"2026-06-12",{"date":113,"type":45},"2025-06-09",{"date":115,"type":20},"2027-12",{"name":117,"class":85},"GenomeFrontier Therapeutics TW Co., Ltd.",1,{"id":120,"slug":121,"hasResults":11,"nctId":122,"briefTitle":123,"officialTitle":124,"acronym":4,"eligibilityCriteria":125,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":126,"targetDuration":4,"studyType":21,"phases":128,"briefSummary":130,"conditions":131,"keywords":136,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":139,"lastUpdatePostDateStruct":140,"startDateStruct":141,"completionDateStruct":143,"leadSponsor":145,"locationsCount":4},"100642551","phase-1-a-study-of-rocbrutinib-in-combination-with-lacutoclax-in-patients-with-b-cell-malignancies-100642551","NCT07609862","A Study of Rocbrutinib in Combination With Lacutoclax in Patients With B-Cell Malignancies","A Phase Ib\u002FII, Open-Label, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of BTK Inhibitor Rocbrutinib in Combination With BCL-2 Inhibitor Lacutoclax in Patients With B-Cell Malignancies","Inclusion Criteria:\n\n1. Age ≥18 years, regardless of sex.\n2. Ib: Histologically confirmed diagnosis of CLL\u002FSLL (per 2018 iwCLL criteria) or B-cell malignancies (per 2022 WHO classification), including: MCL, DLBCL, FL, and WM. Must have received at least one prior line of systemic therapy, with documented disease progression or intolerance.\n\n   II: For Treatment-naïve (TN) CLL\u002FSLL patients: Must meet iwCLL treatment indications and no prior systemic therapy. For R\u002FR CLL\u002FSLL patients: at least one prior systemic therapy with documented disease progression or intolerance.\n3. Have at least one measurable lesion.\n4. Phase Ib: ECOG performance status ≤1; phase II: ECOG performance status ≤2.\n5. Life expectancy ≥ 12 weeks.\n6. Adequate coagulation function, liver and kidney function, bone marrow hematopoietic function.\n7. Male patients and female patients of childbearing potential must agree to use effective contraception during the study and for 90 days after the last dose of study treatment. Female patients of childbearing potential must have a negative pregnancy test before study treatment and must not be breastfeeding. Male patients must not donate sperm during the study and for 90 days after the last dose.\n8. Participation is voluntary, requiring signed informed consent and compliance with the treatment regimen and visit schedule.\n\nExclusion Criteria:\n\n1. Known hypersensitivity or intolerance to Rocbrutinib, Lacutoclax, or any of their excipients; prior treatment with any BCL-2 inhibitor; or prior treatment with both covalent and non-covalent BTK inhibitors.\n2. Use of systemic corticosteroids at doses equivalent to \\>20 mg\u002Fday of prednisone for ≥3 days within 7 days prior to the first dose.\n3. History of or currently suspected Richter's syndrome.\n4. Known or suspected central nervous system (CNS) involvement.\n5. Prior allogeneic hematopoietic stem cell transplantation (allo-HSCT), or autologous hematopoietic stem cell transplantation (auto-HSCT) or chimeric antigen receptor T-cell (CAR-T) therapy within 90 days before the first dose of study treatment.\n6. Received antitumor therapy, investigational agents, major surgery, severe trauma, or live attenuated vaccines within 4 weeks or 5 half-lives prior to the first dose of study treatment.\n7. Received herbal medicines for antitumor treatment, or localized radiotherapy within 14 days prior to the first dose of study treatment.\n8. Use of moderate or strong CYP3A inhibitors within 7 days prior to the first dose of study treatment, or consumption of grapefruit, grapefruit juice, starfruit, or Seville oranges within 3 days prior to prior to the first dose.\n9. History of other active malignancies within the past 3 years, except for curatively treated basal cell carcinoma, localized squamous cell carcinoma of the skin, carcinoma in situ of the cervix or breast, or other malignancies considered cured.\n10. Any severe and\u002For uncontrolled systemic disease, or any other condition that, in the opinion of the investigator, makes the patient unsuitable for participation in the study.\n11. Any of the following events within 6 months prior to the first dose: Symptomatic arrhythmia, myocardial infarction, intracranial hemorrhage, or Stroke.\n12. Impaired cardiac function.\n13. Any uncontrolled systemic infection.\n14. Conditions that may impair oral drug administration or significantly affect absorption or pharmacokinetics of the study drug.\n15. Unable to discontinue moderate or strong CYP3A inhibitors or inducers, P-gp (P-glycoprotein) inhibitors, sensitive substrates of OATP1B3 or CYP2C8 during the study period.\n16. Received vaccination with any live-attenuated vaccines within 4 weeks prior to the first dose of study treatment.\n17. Evidence of an active bleeding constitution or a history of significant hemorrhagic disorders.\n18. Requirement for ongoing therapy with warfarin or other vitamin K antagonists.\n19. Presence of an active, uncontrolled, or symptomatic autoimmune disease that requires systemic treatment.\n20. Any other condition that, in the investigator's judgment, makes the patient unsuitable for study participation.",{"count":127,"type":20},92,[99,129],"PHASE2","BTK inhibitors and BCL-2 inhibitors have demonstrated significant clinical activity in mature B-cell malignancies, and combination therapy may provide improved clinical benefit. This is a multi-center, open-label, single-arm Phase Ib\u002FII clinical study. The purpose of this clinical trial is to investigate the safety, tolerability, pharmacokinetics, and preliminary efficacy of Rocbrutinib, a fourth-generation Bruton tyrosine kinase inhibitor (BTKi), in combination with the BCL-2 inhibitor Lacutoclax in patients with mature B-cell malignancies. The Phase Ib will use a classic 3+3 dose-escalation design to evaluate dose-limiting toxicities (DLTs), determine the maximum tolerated dose (MTD), and identify the recommended dosing regimen. The Phase II portion is intended to further evaluate the efficacy and safety of the combination therapy.",[132,133,27,134,135],"Mantle Cell Lymphoma (MCL)","Diffuse Large B-Cell Lymphoma (DLBCL)","Waldenström Macroglobulinemia (WM)","Chronic Lymphocytic Leukemia\u002FSmall Lymphocytic Lymphoma (CLL\u002FSLL)",[137,33,138],"mature B-cell malignancies","BCL-2 inhibitor","2026-06-07",{"date":109,"type":45},{"date":142,"type":20},"2026-05-30",{"date":144,"type":20},"2033-05-30",{"name":146,"class":85},"Guangzhou Lupeng Pharmaceutical Company LTD.",{"id":148,"slug":149,"hasResults":11,"nctId":150,"briefTitle":151,"officialTitle":152,"acronym":153,"eligibilityCriteria":154,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":155,"targetDuration":4,"studyType":21,"phases":156,"briefSummary":158,"conditions":159,"keywords":162,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":175,"lastUpdatePostDateStruct":176,"startDateStruct":178,"completionDateStruct":180,"leadSponsor":182,"locationsCount":185},"100631548","phase-2-nexcar19-talikabtagene-autoleucel-in-relapsedrefractory-b-cell-malignancies-nexcar19-100631548","NCT07502118","NexCAR19 (Talikabtagene Autoleucel) in Relapsed\u002FRefractory B-Cell Malignancies (NexCAR19)","An Open-Label, Multicenter Phase 2-3 Clinical Study of Anti-CD19 Chimeric Antigen Receptor T Cells (Talikabtagene Autoleucel) in Patients With Relapsed\u002FRefractory B-Cell Malignancies (NexCAR19)","NexCAR19","Inclusion Criteria\n\n1. All participants must meet Inclusion Criteria 1-13.\n\n   Additionally:\n2. High-grade lymphoma subjects must meet Criteria 14-18.\n3. Other B-cell lymphoma subjects must meet Criteria 19-24.\n4. B-ALL subjects must meet Criteria 25-29.\n\nGeneral Inclusion Criteria (Applicable to All Cohorts)\n\n1. Age ≥18 years.\n2. Patients approved for leukapheresis by the CAR-T cell treatment council.\n3. ECOG performance status \\\u003C2.\n4. Life expectancy ≥12 weeks.\n5. Renal Function: Estimated creatinine clearance ≥60 mL\u002Fmin (Cockcroft-Gault) → fludarabine\u002Fcyclophosphamide lymphodepletion.\n\n   In lymphoma cohort patients with creatinine clearance 30-60 mL\u002Fmin, bendamustine may be used as an alternative due to cumulative fludarabine toxicity and neurotoxicity risk.\n6. Liver Function:\n\n   1. ALT and AST ≤3 × ULN unless attributable to underlying malignancy.\n   2. Total bilirubin ≤2 × ULN except in Gilbert syndrome, isolated unconjugated hyperbilirubinemia, or if attributable to underlying malignancy.\n7. Hemodynamically stable with LVEF ≥45% (confirmed by echocardiography or MUGA scan).\n8. Baseline oxygen saturation \\>92% on room air.\n9. ANC ≥500\u002FµL (may be waived if cytopenia due to underlying malignancy at investigator discretion).\n10. Platelet count ≥50,000\u002FµL (may be waived if cytopenia due to underlying malignancy at investigator discretion).\n11. Negative serum or urine pregnancy test (within 24 hours prior to conditioning therapy) in women of childbearing potential; also negative prior to leukapheresis.\n12. Sexually active patients (women of childbearing potential and all men) must use highly effective contraception for ≥12 months after CAR-T infusion.\n13. Written informed consent provided.\n\n    High-Grade Lymphoma - Additional Inclusion Criteria (14-18)\n14. Histologically confirmed previously treated:\n\n    1. Diffuse large B-cell lymphoma (DLBCL)\n    2. Primary mediastinal B-cell lymphoma\n    3. Transformed indolent B-cell lymphoma\n    4. Follicular lymphoma Grade 3B\n    5. High-grade B-cell lymphoma\n15. Chemotherapy-refractory disease defined as:\n\n    1. Primary refractory disease\n    2. Best response to last chemotherapy = PD or SD (biopsy confirmed)\n    3. Progression\u002Frelapse ≤12 months after autologous SCT\n    4. Relapse ≤12 months after first-line CR (biopsy confirmed)\n    5. Relapse beyond 12 months if auto-SCT not feasible\n16. Not eligible for or unwilling to undergo autologous SCT.\n17. Must have received anti-CD20 monoclonal antibody and anthracycline-containing regimen. Transformed lymphoma subjects must have received ≥2 prior systemic lines.\n18. Measurable disease per International Working Group (IWG) criteria.\n\n    Other B-Cell Lymphomas - Additional Inclusion Criteria (19-24)\n19. Histologically confirmed:\n\n    1. Mantle Cell Lymphoma (Cyclin D1 overexpression or t(11;14))\n    2. Follicular Lymphoma Grade I-IIIA\n    3. Marginal Zone Lymphoma\n20. Relapsed or refractory disease:\n\n    1. MCL: ≤5 prior regimens including:\n\n       * Anthracycline or bendamustine\n       * Anti-CD20 antibody\n       * BTK inhibitor (ibrutinib or acalabrutinib; intolerance allowed)\n    2. FL\u002FMZL: Progression after ≥2 combination chemoimmunotherapy regimens (single-agent CD20 or splenectomy not counted).\n21. Radiologically measurable disease at screening\n\n    1. per revised IWG (Cheson 2007): ≥1 measurable lesion\n    2. Previously irradiated lesions measurable only if progression documented\n    3. If only nodal disease: ≥1 node ≥2 cm\n22. No known active CNS lymphoma involvement.\n23. Prior therapy toxicities resolved to ≤Grade 1 (except alopecia).\n24. Prior autologous HCT, POD24 status, and prior PI3K inhibitor therapy allowed.\n\n    B-Cell Acute Lymphoblastic Leukemia (B-ALL) - Additional Inclusion Criteria (25-29)\n25. Relapsed\u002FRefractory B-ALL meeting one of:\n\n    1. Primary refractory disease\n    2. First relapse ≤12 months\n    3. ≥2 prior systemic lines\n    4. Post-allogeneic SCT relapse (≥100 days post-transplant; off immunosuppression ≥4 weeks)\n    5. Ph+ disease:\n\n       * TKI intolerance\n       * Relapsed\u002Frefractory after ≥2 TKIs\n       * No alternative TKI option\n    6. Ineligible for allogeneic SCT due to\n\n       * comorbidity,\n       * conditioning contraindication,\n       * no donor,\n       * prior SCT,\n       * or refusal (documented).\n26. Morphological bone marrow disease.\n27. CD19 tumor expression documented within 3 months (BM or PB by flow cytometry).\n28. Absolute lymphocyte count ≥100\u002FµL.\n29. ≥3 half-lives elapsed since prior immune checkpoint inhibitor or stimulatory therapy\n\nExclusion Criteria\n\n1. All participants must meet Exclusion Criteria 1-14.\n\n   Additionally:\n2. High-grade lymphoma: 15-22\n3. Low-grade lymphoma: 23-24\n4. B-ALL: 25\n\nGeneral Exclusion Criteria (All Cohorts)\n\n1. Uncontrolled life-threatening infection (e.g., positive blood culture ≤72h before infusion).\n2. HIV positive.\n3. Active HBV replication or active HCV (RNA positive).\n4. Unstable angina or MI within 6 months.\n5. Uncontrolled cardiac arrhythmia.\n6. Concurrent malignancy except adequately treated non-melanoma skin cancer, in situ carcinoma (≥3 years disease-free), or completely resected malignancy in CR ≥3 years.\n7. Pregnant or breastfeeding.\n8. Hypersensitivity to CAR-T product excipients.\n9. Active autoimmune\u002Finflammatory neurologic disorders.\n10. Primary immunodeficiency.\n11. Short-acting leukemia\u002Flymphoma therapies must be stopped \\>72h before leukapheresis and infusion.\n12. Burkitt lymphoma\u002Fleukemia.\n13. Steroids must be discontinued \\>72h prior (\\\u003C12 mg\u002Fm²\u002Fday hydrocortisone equivalent allowed).\n14. Investigator deems subject unable to comply.\n\n    High-Grade Lymphoma - Additional Exclusion (15-22)\n15. Active CNS involvement.\n16. Prior allogeneic HSCT.\n17. Systemic immunosuppressives not discontinued ≥1 weeks before leukapheresis\u002Finfusion.\n18. Anti-proliferative therapy not stopped ≥1 weeks prior.\n19. Cytotoxic drugs not stopped ≥1 week prior.\n20. A minimum interval of ≥4 weeks is required between donor lymphocyte infusion (DLI) and leukapheresis, and ≥4 weeks between DLI and CAR-T cell infusion. This requirement applies to prior antibody-based therapies, including anti-CD20, anti-CD22, anti-CD79a, and similar agents.\n21. CNS prophylaxis not stopped \\>1 week prior.\n22. Radiation not stopped ≥2 days before leukapheresis and ≥1 week before infusion.\n\n    Low-Grade Lymphoma - Additional Exclusion (23-24)\n23. Live vaccine ≤6 weeks before conditioning.\n24. Tumor mass effect requiring urgent treatment.\n\n    B-ALL - Additional Exclusion (25)\n25. Acute graft-versus-host disease (GVHD) of Grade II-IV according to the Glucksberg criteria or Grade B-D according to the IBMTR index; or acute or chronic GVHD requiring systemic treatment within 4 weeks prior to enrollment.",{"count":19,"type":20},[129,157],"PHASE3","The NexCAR19 study is a national, open-label, multicenter Phase 2-3 clinical trial designed to evaluate the efficacy and safety of the anti-CD19 chimeric antigen receptor (CAR) T-cell product, Talikabtagene Autoleucel, in patients with relapsed\u002Frefractory B-cell malignancies, including B-cell Acute Lymphoblastic Leukemia (B-ALL) and Non-Hodgkin Lymphoma. The study is supported by the Presidency of Turkish Health Institutes (TÜSEB) and will be conducted at four centers.\n\nThis therapy is based on collecting the patient's own T cells, genetically modifying them in a laboratory to recognize the CD19 antigen, and reinfusing them into the patient. The goal is to target leukemia or lymphoma cells and achieve disease control.\n\nThe primary objective is to assess the overall response rate at Day 28 after infusion and to evaluate the safety profile of the treatment. Secondary objectives include assessment of complete response rate, duration of response, overall survival, and progression-free survival, as well as the frequency and severity of cytokine release syndrome (CRS), neurotoxicity (ICANS), and other treatment-related adverse events. In addition, the in vivo persistence and immunological effects of CAR-T cells will be evaluated.\n\nEligible patients must be 18 years of age or older, have an adequate performance status, sufficient organ function, and meet disease-specific eligibility criteria. Key exclusion criteria include active severe infection, uncontrolled cardiac disease, active central nervous system involvement (where applicable), HIV or active hepatitis infection, pregnancy, and severe immunodeficiency.\n\nThe treatment process includes leukapheresis for cell collection, administration of lymphodepleting chemotherapy if required, followed by a single infusion of CAR-T cells. Patients will be closely monitored after infusion, particularly during the early period, and both early and late adverse events, as well as treatment response, will be regularly assessed.\n\nA total of 40 patients are planned to be enrolled. The overall clinical follow-up period, including short- and long-term monitoring, is expected to last approximately 30 months. Data will be analyzed using appropriate statistical methods.",[160,161,133,106,27],"Relapsed\u002FRefractory B-cell Acute Lymphoblastic Leukemia (B-ALL)","Relapsed\u002FRefractory Non-Hodgkin Lymphoma",[163,164,165,166,167,168,169,170,171,172,173,174],"Relapsed\u002FRefractory B-Cell Malignancies","B-Cell Acute Lymphoblastic Leukemia (B-ALL)","Non-Hodgkin Lymphoma","High-Grade Lymphoma","Low-Grade Lymphoma","CD19","CAR-T Cell Therapy","Talikabtagene Autoleucel","Autologous T Cells","Adoptive Cell Therapy","Cytokine Release Syndrome (CRS)","ICANS","2026-03-24",{"date":177,"type":45},"2026-03-30",{"date":179,"type":45},"2025-09-11",{"date":181,"type":20},"2030-01-01",{"name":183,"class":184},"Health Institutes of Turkey","OTHER_GOV",4,{"id":187,"slug":188,"hasResults":11,"nctId":189,"briefTitle":190,"officialTitle":191,"acronym":4,"eligibilityCriteria":192,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":193,"targetDuration":4,"studyType":21,"phases":195,"briefSummary":196,"conditions":197,"keywords":4,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":201,"lastUpdatePostDateStruct":202,"startDateStruct":204,"completionDateStruct":206,"leadSponsor":208,"locationsCount":210},"100602318","phase-1-this-is-a-phase-1-study-to-evaluate-the-safety-of-ltz-301-in-patients-with-non-hodgkin-lymphoma-100602318","NCT07121946","This is a Phase 1 Study to Evaluate the Safety of LTZ-301 in Patients With Non-Hodgkin Lymphoma","A Phase 1, Open-label, Multicenter Study of LTZ-301 in Subjects With Relapsed\u002FRefractory Non-Hodgkin Lymphoma","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Relapsed or refractory to at least 2 prior systemic treatment regimens\n* At least 1 bi-dimensionally measurable lesion (≥ 1.5 cm) in longest dimension\n* Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1\n* Adequate bone marrow, cardiac, pulmonary, renal, and hepatic function\n\nExclusion Criteria:\n\n* CLL, or Richters transformation\n* Prior solid organ transplant\n* Prior allogeneic stem cell transplant\n* ASCT within 100 days prior to the first LTZ-301 administration\n* Prior CAR-T within 60 days prior to the first LTZ-301 administration\n* Current central nervous system (CNS) lymphoma\n* Known history of human immunodeficiency virus (HIV) seropositivity\n* Active autoimmune disease\n* History of clinically significant cardiovascular disease\n* symptomatic deep vein thrombosis (DVT) within 3 months of enrollment\n* History of other malignancy within 3 years prior to screening",{"count":194,"type":20},42,[99],"This study is a first-in-human (FIH), Phase 1, multicenter, open-label study to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, and evaluate the preliminary anti-tumor activity of LTZ-301 administered as a single agent in adult subjects with relapsed or refractory B-cell non-Hodgkin lymphoma",[198,199,132,27,200],"Non-Hodgkin Lymphoma Refractory\u002F Relapsed","DLBCL - Diffuse Large B Cell Lymphoma","Marginal Zone Lymphoma (MZL)","2026-02-06",{"date":203,"type":45},"2026-02-10",{"date":205,"type":45},"2026-01-29",{"date":207,"type":20},"2028-02",{"name":209,"class":85},"LTZ Therapeutics, Inc.",5,{"id":212,"slug":213,"hasResults":11,"nctId":214,"briefTitle":215,"officialTitle":216,"acronym":4,"eligibilityCriteria":217,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":95,"enrollmentInfo":218,"targetDuration":4,"studyType":21,"phases":220,"briefSummary":221,"conditions":222,"keywords":224,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":229,"lastUpdatePostDateStruct":230,"startDateStruct":232,"completionDateStruct":234,"leadSponsor":236,"locationsCount":238},"100598901","phase-2-relmacabtagene-autoleucel-combined-with-sintilimab-for-relapsedrefractory-b-cell-lymphoma-100598901","NCT07077512","Relmacabtagene Autoleucel Combined With Sintilimab for Relapsed\u002FRefractory B-cell Lymphoma","A Single-arm, Phase II Clinical Study of Relmacabtagene Autoleucel Combined With Sintilimab for Relapsed\u002FRefractory B-cell Lymphoma.","Inclusion Criteria:\n\n1. The patient must be aware of and voluntarily sign the informed consent form (ICF).\n2. Aged between 18 and 70 years, both male and female.\n3. Pathologically diagnosed with DLBCL, FL, or MCL, with histological confirmation of CD19 positivity (immunohistochemistry or flow cytometry, with flow cytometry used for re-evaluation if immunohistochemistry is CD19-negative).\n4. The patient must be willing to receive regorafenib and sintilimab treatment and be deemed suitable for this treatment by the investigator.\n5. Relapsed\u002Frefractory DLBCL, FL, or MCL.\n6. At least one measurable or evaluable lesion.\n7. Eastern Cooperative Oncology Group (ECOG) performance status score of 0-2.\n8. Expected survival of ≥3 months.\n9. Adequate function of the heart, lungs, liver, kidneys, and other organs.\n\nExclusion Criteria:\n\n1. History of another malignancy that has not been in complete remission for at least 2 years, except for: non-melanoma skin cancer, completely resected stage I tumors with low recurrence potential, treated localized prostate cancer, biopsy-confirmed cervical carcinoma in situ, or squamous intraepithelial lesions detected by Pap smear and so on.\n2. Active Hepatitis B: a) Positive for Hepatitis B surface antigen (HBsAg) and\u002For Hepatitis B core antibody (HBcAb) , with HBV-DNA below the lower limit of the reference value can be included.\n3. Hepatitis C, HIV, or syphilis infection.\n4. Uncontrolled systemic fungal, bacterial, viral, or other infections.\n5. Acute or chronic graft-versus-host disease (GVHD).\n6. Known hypersensitivity or allergy to any study drug or excipient.\n7. Clinically significant central nervous system (CNS) disease or symptoms, such as epilepsy, seizures, paralysis, aphasia, stroke, severe brain injury, dementia, Parkinson's disease, cerebellar disease, organic brain syndrome, or psychiatric illness.\n8. Pregnant or breastfeeding women, and women of childbearing age who do not wish to use contraception.\n9. Mentally ill individuals or those unable to provide informed consent.\n10. The investigator deems the patient unsuitable for the study due to medical, psychological, familial, social, or geographical reasons or an inability to comply with the study protocol.\n11. Previous CAR-T cell therapy or other gene-modified T-cell treatments.\n12. Previous CD19-targeted therapy.\n13. Previous allogeneic hematopoietic stem cell transplantation.",{"count":219,"type":20},30,[129],"This is a prospective, single-arm, multicenter, phase II clinical trial to evaluate the efficacy and safety of Relmacabtagene Autoleucel in combination with the Sintilimab regimen for the treatment of relapsed\u002Frefractory B-cell lymphoma",[223,132,27],"Large B Cell Diffuse Lymphoma",[225,226,227,228],"Relmacabtagene Autoleucel","Sintilimab","CD19 Positive","B cell lymphoma","2026-01-20",{"date":231,"type":45},"2026-01-21",{"date":233,"type":45},"2025-09-15",{"date":235,"type":20},"2027-07-15",{"name":237,"class":52},"Sun Yat-sen University",3,{"id":240,"slug":241,"hasResults":11,"nctId":242,"briefTitle":243,"officialTitle":244,"acronym":4,"eligibilityCriteria":245,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":246,"targetDuration":4,"studyType":21,"phases":247,"briefSummary":249,"conditions":250,"keywords":253,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":179,"lastUpdatePostDateStruct":257,"startDateStruct":259,"completionDateStruct":261,"leadSponsor":263,"locationsCount":118},"100605881","early-phase-1-novel-bispecific-abtcr-anti-cd19cd22-t-cells-in-relapsed-or-refractory-b-cell-lymphoma-100605881","NCT07168291","Novel Bispecific AbTCR (Anti-CD19\u002FCD22)-T Cells in Relapsed or Refractory B-cell Lymphoma","The Safety and Efficacy of Novel Bispecific AbTCR (Anti-CD19\u002FCD22)-T Cells in Patients With Relapsed or Refractory B-cell Lymphoma: An Open-label, Single-arm Clinical Study","Inclusion Criteria:\n\n1. Age≥ 18 years;\n2. Pathologically diagnosed CD19+\u002FCD22+ B-cell lymphoma;\n3. Relapsed or refractory after at least two prior lines of therapy;\n4. Patient's main organs functioning well:\n\n   1. Cardiac function: Left ventricular ejection fraction ≥50%;\n   2. Liver function: ALT and AST ≤2.5 × upper limit of normal (ULN), total bilirubin ≤2 × ULN;\n   3. Renal function: Serum creatinine ≤3.0 mg\u002FdL (≤260 μmol\u002FL);\n   4. Pulmonary function: ≤CTCAE grade 1 dyspnea and Indoor oxygen saturation ≥92%;\n   5. Adequate bone marrow function as assessed by the investigator to receive lymphodepleting chemotherapy;\n5. Adequate vascular access for leukapheresis;\n6. Women of childbearing potential (all women physiologically capable of becoming pregnant) must agree to use highly effective contraception for 1 year after AbTCR (anti-CD19\u002FCD22)-T cell infusion, such as copper-containing intrauterine device, hormonal implants, or tubal ligation; male subjects with partners of childbearing potential must agree to use effective barrier contraception for 1 year after AbTCR (anti-CD19\u002FCD22)-T cell infusion;\n7. Patient or his or her legal guardian voluntarily participates in and signs an informed consent form.\n\nExclusion Criteria:\n\n1. Lymphoma involving only the central nervous system (CNS), or secondary CNS lymphoma patients judged by the investigator to be at high risk for AbTCR (anti-CD19\u002FCD22)-T cell therapy;\n2. History of other malignancies not in complete remission for at least 2 years (the following conditions are exempt from the 2-year restriction: non-melanoma skin cancer, completely resected stage I tumors with low risk of recurrence, treated localized prostate cancer, biopsy-confirmed cervical carcinoma in situ, or PAP smear showing squamous intraepithelial lesion);\n3. Any of the following at screening:\n\n   1. Positive hepatitis B surface antigen (HBsAg) (regardless of hepatitis B virus DNA copy number);\n   2. Positive hepatitis B core antibody (HBcAb) with increased hepatitis B virus DNA copy number;\n   3. Hepatitis C, human immunodeficiency virus (HIV), or syphilis infection;\n4. Deep vein thrombosis (DVT) or pulmonary embolism (PE) within 3 months prior to signing informed consent;\n5. Ongoing anticoagulant therapy for deep vein thrombosis (DVT) or pulmonary embolism (PE) within 3 months prior to signing informed consent;\n6. Uncontrolled systemic fungal, bacterial, viral, or other infection;\n7. Acute or chronic graft-versus-host disease (GvHD);\n8. History of any of the following cardiovascular diseases within the past 6 months: Class III or IV heart failure as defined by the New York Heart Association (NYHA), cardiac angioplasty or stenting, myocardial infarction, unstable angina, or other clinically significant heart disease;\n9. History of or current clinically significant CNS disease at screening, such as epilepsy, seizures, paralysis, aphasia, stroke, severe brain injury, dementia, Parkinson's disease, cerebellar disease, organic brain syndrome, or psychiatric illness;\n10. Pregnant or breastfeeding women. Women of childbearing potential must have a negative serum pregnancy test within 48 hours prior to starting lymphodepleting chemotherapy;\n11. Use of any of the following drugs or treatments within the specified timeframes prior to leukapheresis:\n\n    1. Alemtuzumab within 6 months prior to leukapheresis;\n    2. Cladribine within 3 months prior to leukapheresis;\n    3. Fludarabine within 3 months prior to leukapheresis;\n    4. Anti-CD20 monoclonal antibody within 7 days prior to leukapheresis;\n    5. Venetoclax within 4 days prior to leukapheresis;\n    6. Idelalisib within 2 days prior to leukapheresis;\n    7. Lenalidomide within 1 day prior to leukapheresis;\n    8. Therapeutic doses of corticosteroids (defined as prednisone or equivalent \\>20 mg\u002Fday) within 7 days prior to leukapheresis; physiological replacement, topical, and inhaled steroids are permitted;\n    9. Non-lymphocytotoxic chemotherapy within 1 week prior to leukapheresis. Oral chemotherapy drugs are allowed if at least 3 half-lives have passed prior to leukapheresis;\n    10. Lymphocytotoxic chemotherapy (e.g., cyclophosphamide, ifosfamide, bendamustine, chlorambucil, or melphalan) within 2 weeks prior to leukapheresis;\n    11. Investigational drugs within 4 weeks prior to leukapheresis. However, subjects who had no response or disease progression during experimental treatment and for whom at least 3 half-lives have passed since the last dose prior to leukapheresis are allowed;\n    12. GvHD therapy (e.g., calcineurin inhibitors, methotrexate or other chemotherapeutic agents, mycophenolate, rapamycin, thalidomide, immunosuppressive antibodies such as anti-TNF, anti-IL6, or anti-IL6R) within 4 weeks prior to leukapheresis and AbTCR (anti-CD19\u002FCD22)-T cell infusion;\n    13. Donor lymphocyte infusion (DLI) within 6 weeks prior to AbTCR (anti-CD19\u002FCD22)-T cell administration;\n    14. Radiotherapy within 6 weeks prior to leukapheresis, including large bone marrow areas such as the sternum or pelvis. Patients with progressive disease at irradiated sites or PET-positive lesions at non-irradiated sites are eligible. Radiotherapy to a single site is allowed within 2 weeks prior to leukapheresis if there are PET-positive lesions at other non-irradiated sites;\n    15. If prior immunotherapy such as anti-PD1 or anti-PD-L1 was used, at least 5 half-lives must have passed between the last dose and AbTCR (anti-CD19\u002FCD22)-T cell infusion;\n12. Prior allogeneic hematopoietic stem cell transplantation;\n13. Other conditions considered inappropriate by the researcher.",{"count":238,"type":20},[248],"EARLY_PHASE1","This is an open-lable, single arm, non-randomized study to evaluate the primary safety and efficacy of the novel bispecific AbTCR (anti-CD19\u002FCD22)-T cells in patients with relapsed or refractory B-cell lymphoma",[251,27,252],"Diffuse Large B Cell Lymphoma (DLBCL)","Burkitt Lymphoma",[254,255,256],"AbTCR-T","CD19\u002FCD22","B-cell lymphoma",{"date":258,"type":45},"2025-09-17",{"date":260,"type":20},"2025-12-31",{"date":262,"type":20},"2028-12-31",{"name":264,"class":52},"First Affiliated Hospital Xi'an Jiaotong University",{"id":266,"slug":267,"hasResults":11,"nctId":268,"briefTitle":269,"officialTitle":270,"acronym":4,"eligibilityCriteria":271,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":272,"enrollmentInfo":273,"targetDuration":4,"studyType":21,"phases":274,"briefSummary":275,"conditions":276,"keywords":277,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":281,"lastUpdatePostDateStruct":282,"startDateStruct":284,"completionDateStruct":286,"leadSponsor":287,"locationsCount":118},"100589847","phase-2-zanubrutinib-combined-with-g-cvp-in-previously-untreated-fl-100589847","NCT06959732","Zanubrutinib Combined With G-CVP in Previously Untreated FL","Efficacy and Safety of Zanubrutinib Combined With G-CVP Regimen in Previously Untreated Follicular Lymphoma","Inclusion Criteria:\n\nPatients must meet all of the following criteria to be eligible:\n\n1\\. Histologically confirmed CD20-positive FL (grades 1, 2, or 3a), diagnosed according to the WHO 2022 criteria; 2, Clear indication for treatment: symptoms affecting normal work and life; end-organ dysfunction; cytopenia due to bone marrow involvement by lymphoma; bulky disease (per GELF criteria); persistent or rapidly progressive disease; 3. No prior systemic therapy for lymphoma; 4. Age 18-80 years; 5. Eastern cooperative oncology group (ECOG) performance status (PS) \\\u003C 2; 6. Expected survival \\> 2 years; 7. At least one measurable lesion with a longest diameter ≥ 1.5 cm or extranodal lesion ≥ 1 cm; 8. Willingness to participate in the study and comply with treatment and follow-up.\n\nExclusion Criteria:\n\nPatients will be excluded if they meet any of the following criteria:\n\n1. Pregnant or breastfeeding women;\n2. Abnormal liver or kidney function, defined as: serum direct\u002Findirect bilirubin, alanine aminotransferase (ALT), aspartate aminotransferase (AST), or serum creatinine \\> 2 × upper limit of normal (ULN); creatinine clearance \\\u003C 60 mL\u002Fmin (unless due to lymphoma involvement);\n3. History of deep vein thrombosis (DVT) or pulmonary embolism (PE) within the past 12 months;\n4. Absolute neutrophil count (ANC) \\\u003C 1.5 × 10⁹\u002FL, platelets \\\u003C 75 × 10⁹\u002FL, or hemoglobin \\\u003C 70 g\u002FL (unless due to bone marrow involvement by lymphoma);\n5. Long-term use of strong or moderate CYP3A inducers;\n6. Known hypersensitivity to any component of the study drug;\n7. Other active malignancies, except: cured non-melanoma skin cancer, cervical carcinoma in situ, localized prostate cancer, superficial bladder cancer, ductal carcinoma in situ, or other malignancies with disease-free survival \\> 5 years;\n8. Severe concurrent infections;\n9. Drug abuse, medical, psychological, or social conditions that may interfere with study participation or result evaluation;\n10. Investigator-deemed ineligibility for the study.","80 Years",{"count":19,"type":20},[129],"The goal of this clinical trial is to learn the efficacy and safety of zanubrutinib in combination with G-CVP in previously untreated follicular lymphoma patients The main questions it aims to answer are: (1) Efficacy and safety of patients receiving zanubrutinib, obinutuzumab combined with cyclophosphamide, vincristine, and prednisone (CVP) regimen. (2) The difference in efficacy of patients with different minimal residual disease (MRD) status after treatment.\n\nParticipants will receive zanubrutinib combined with G-CVP, maintenance therapy will be determined by the MRD status after treatment.",[27],[27,278,279,280],"Zanubrutinib","Obinutuzumab","CVP","2025-05-04",{"date":283,"type":45},"2025-05-07",{"date":285,"type":45},"2025-01-01",{"date":49,"type":20},{"name":288,"class":52},"Cancer Institute and Hospital, Chinese Academy of Medical Sciences"]